Our RNAseq data on the GBM infiltrative margin based on 5ALA fluorescence-based isolation, offers a clinical validation of the OLA drug target (i.e., PARP-1) at the outset for preclinical drug delivery efficacy assessment, as PARP-1 mRNA expression was detected in infiltrative GBM cells at comparable levels to intra-tumor regions. The gene discussed is PARP1; the disease is glioblastoma.